Background: The aim is to investigate whether secreted protein acidic and rich in cysteine (SPARC) expression could be considered as an independent prognostic factor in pancreatic ductal adenocarcinoma (PDAC). Methods: The expression of SPARC in the tumor species was detected by immunochemistry and the effect of SPARC on the prognosis was analyzed by Kaplan-Meier and Cox proportional hazard models. Results: Positive SPARC expressions recognized in tumor and stroma were 31.33% and 64.66% respectively. The expression of SPARC in stroma was closely correlated with differentiation, vascular invasion and was an indicator for predicting poor outcome after surgery in Kaplan-Meier analysis. Univariate analysis and multivariate analysis showed the following factors to be significant: perineural invasion (HR = 2.098, 95% CI: 1.144 - 3.847) and stroma positive expression of SPARC (HR = 2.120, 95% CI: 1.307 - 3.440). Conclusions: High expression of SPARC in stroma was a promising pathological marker to predict the poor outcome in patients with pancreatic ductal adenocarcinoma.
Siegel, R.L., Miller, K.D. and Jemal, A. (2016) Cancer Statistics, 2016. CA: A Cancer Journal for Clinicians, 66, 7-30. https://doi.org/10.3322/caac.21332
Wolfgang, C.L., Herman, J.M., Laheru, D.A., Klein, A.P., Erdek, M.A., Fishman, E.K. and Hruban, R.H. (2013) Recent Progress in Pancreatic Cancer. CA: A Cancer Journal for Clinicians, 63, 318-348. https://doi.org/10.3322/caac.21190
Yan, T.T., Fu, X.L., Li, J., Bian, Y.N., Liu, D.J., Hua, R., Ren, L.L., Li, C.T., Sun, Y.W., Chen, H.Y., Fang, J.Y. and Hong, J. (2015) Downregulation of RPL15 May Predict Poor Survival and Associate with Tumor Progression in Pancreatic Ductal Adenocarcinoma. Oncotarget, 6, 37028-37042. https://doi.org/10.18632/oncotarget.5939
Reed, M.J. and Sage, E.H. (1996) SPARC and the Extracellular Matrix: Implications for Cancer and Wound Repair. Current Topics in Microbiology and Immunology, 213, 81-94. https://doi.org/10.1007/978-3-642-61107-0_6
Hrabchak, C., Ringuette, M. and Woodhouse, K. (2008) Recombinant Mouse SPARC Promotes Parietal Endoderm Differentiation and Cardiomyogenesis in Embryoid Bodies. Biochemistry and Cell Biology, 86, 487-499. https://doi.org/10.1139/O08-141
Maloney, S.C., Marshall, J.C., Antecka, E., Orellana, M.E., Fernandes, B.F., Martins, C., Castiglione, E., DI. Cesare. S., Logan, P. and Burnier, Jr., M.N. (2009) SPARC Is Expressed in Human Uveal Melanoma and Its Abrogation Reduces Tumor Cell Proliferation. Anticancer Research, 29, 3059-3064.
Shi, D., Jiang, K., Fu, Y., Fang, R., Liu, X.I. and Chen, J. (2016) Overexpression of SPARC Correlates with Poor Prognosis in Patients with Cervical Carcinoma and Regulates Cancer Cell Epithelial-Mesenchymal Transition, Oncology Letters, 11, 3251-3258. https://doi.org/10.3892/ol.2016.4399
Kim, J.Y., Jeong, D., Ahn, T.S., Kim, H.J., Park, D.S., Park, S.Y., Bae, S.B., Lee, S., Lee, S.S., Lee, M.S., Cho, H.D. and Baek, M.J. (2013) Xpression of Secreted Protein Acidic and Rich in Cysteine in the Stroma of a Colorectal Carcinoma Is Associated with Patient Prognosis. Annals of Coloproctology, 29, 93-99. https://doi.org/10.3393/ac.2013.29.3.93
Wang, H.Y., Li, Y.Y., Shao, Q., Hou, J.H., Wang, F., Cai, M.B., Zeng, Y.X. and Shao, J.Y. (2012) Secreted Protein Acidic and Rich in Cysteine (SPARC) Is Associated with Nasopharyngeal Carcinoma Metastasis and Poor Prognosis. Journal of Translational Medicine, 10, 27. https://doi.org/10.1186/1479-5876-10-27
Kato, Y., Nagashima, Y., Baba, Y., Kawano, T., Furukawa, M., Kubota, A., Yanoma, S., Imagawa-Ishiguro, Y., Satake, K., Taguchi, T., Hata, R., Mochimatsu, I., Aoki, I., Kameda, Y., Inayama, Y. and Tsukuda, M. (2005) Expression of SPARC in Tongue Carcinoma of Stage II Is Associated with Poor Prognosis: An Immunohistochemical Study of 86 Cases. International Journal of Molecular Medicine, 16, 263-268. https://doi.org/10.3892/ijmm.16.2.263
Chin, D., Boyle, G.M., Williams, R.M., Ferguson, K., Pandeya, N., Pedley, J., Campbell, C.M., Theile, D.R., Parsons, P.G. and Coman, W.B. (2005) Novel Markers for Poor Prognosis in Head and Neck Cancer. International Journal of Cancer, 113, 789-797. https://doi.org/10.1002/ijc.20608
Koukourakis, M.I., Giatromanolaki, A., Brekken, R.A., Sivridis, E., Gatter, K.C., Harris, A.L. and Sage, E.H. (2003) Enhanced Expression of SPARC/Osteonectin in the Tumor-Associated Stroma of Non-Small Cell Lung Cancer Is Correlated with Markers of Hypoxia/Acidity and with Poor Prognosis of Patients. Cancer Research, 63, 5376-5380.
Podhajcer, O.L., Benedetti, L.G., Girotti, M.R., Prada, F., Salvatierra, E. and Llera, A.S. (2008) The Role of the Matricellular Protein SPARC in the Dynamic Interaction between the Tumor and the Host. Cancer and Metastasis Reviews, 27, 691-705. https://doi.org/10.1007/s10555-008-9146-7
Yiu, G.K., Chan, W.Y., Ng, S.W., Chan, P.S., Cheung, K.K., Berkowitz, R.S. and Mok, S.C. (2001) SPARC (Secreted Protein Acidic and Rich in Cysteine) Induces Apoptosis in Ovarian Cancer Cells. The American Journal of Pathology, 159, 609-622. https://doi.org/10.1016/S0002-9440(10)61732-4
Wong, S.Y., Crowley, D., Bronson, R.T. and Hynes, R.O. (2008) Analyses of the Role of Endogenous SPARC in Mouse Models of Prostate and Breast Cancer. Clinical & Experimental Metastasis, 25, 109-118. https://doi.org/10.1007/s10585-007-9126-2
Seno, T., Harada, H., Kohno, S., Teraoka, M., Inoue, A. and Ohnishi, T. (2009) Downregulation of SPARC Expression Inhibits Cell Migration and Invasion in Malignant Gliomas. International Journal of Oncology, 34, 707-715. https://doi.org/10.3892/ijo_00000197
Strimpakos, A.S., Syrigos, K.N. and Saif, M.W. (2013) Pharmacogenomics in Pancreatic Adenocarcinoma: New Data and Their Clinical Implications. JOP: Journal of the Pancreas, 14, 359-362.
Mantoni, T.S., Schendel, R.R., Rodel, F., Niedobitek, G., Al-Assar, O., Masamune, A. and Brunner, T.B. (2008) Stromal SPARC Expression and Patient Survival after Chemoradiation for Non-Resectable Pancreatic Adenocarcinoma. Journal Cancer Biology & Therapy, 7, 1806-1815. https://doi.org/10.4161/cbt.7.11.6846
Sun, Z.J., Wang, Y., Cai, Z., Chen, P.P., Tong, X.J. and Xie, D. (2008) Involvement of Cyr61 in Growth, Migration, and Metastasis of Prostate Cancer Cells. British Journal of Cancer, 99, 1656-1667. https://doi.org/10.1038/sj.bjc.6604712
Infante, J.R., Matsubayashi, H., Sato, N., Tonascia, J., Klein, A.P., Riall, T.A., Yeo, C., Iacobuzio-Donahue, C. and Goggins, M. (2007) Peritumoral Fibroblast SPARC Expression and Patient Outcome with Resectable Pancreatic Adenocarcinoma. Journal of Clinical Oncology, 25, 319-325. https://doi.org/10.1200/JCO.2006.07.8824
Deng, Y.Z., Yao, F., Li, J.J., Mao, Z.F., Hu, P.T., Long, L.Y., Li, G., Ji, X.D., Shi, S., Guan, D.X., Feng, Y.Y., Cui, L., Li, D.S., Liu, Y., Du, X., Guo, M.Z., Xu, L.Y., Li, E.M., Wang, H.Y. and Xie, D. (2012) RACK1 Suppresses Gastric Tumorigenesis by Stabilizing the β-Catenin Destruction Complex. Gastroenterology, 142, 812-823. https://doi.org/10.1053/j.gastro.2011.12.046
Kapinas, K., Lowther, K.M., Kessler, C.B., Tilbury, K., Lieberman, J.R., Tirnauer, J.S., Campagnola, P. and Delany, A.M. (2012) Bone Matrix Osteonectin Limits Prostate Cancer Cell Growth and Survival. Matrix Biology, 31, 299-307. https://doi.org/10.1016/j.matbio.2012.03.002
Gilles, C., Bassuk, J.A., Pulyaeva, H., Sage, E.H., Foidart, J.M. and Thompson, E.W. (1998) SPARC/Osteonectin Induces Matrix Metalloproteinase 2 Activation in Human Breast Cancer Cell Lines. Cancer Research, 58, 5529-5536.
Briggs, J., Chamboredon, S., Castellazzi, M., Kerry, J.A. and Bos, T.J. (2002) Transcriptional Upregulation of SPARC, in Response to c-Jun Overexpression, Contributes to Increased Motility and Invasion of MCF7 Breast Cancer Cells. Oncogene, 21, 7077-7091. https://doi.org/10.1038/sj.onc.1205857
Shi, Q., Bao, S., Song, L., Wu, Q., Bigner, D.D., Hjelmeland, A.B. and Rich, J.N. (2007) Targeting SPARC Expression Decreases Glioma Cellular Survival and Invasion Associated with Reduced Activities of FAK and ILK Kinases. Oncogene, 26, 4084-4094. https://doi.org/10.1038/sj.onc.1210181
Brekken, R.A. and Sage, E.H. (2001) SPARC, a Matricellular Protein: At the Crossroads of Cell-Matrix Communication. Matrix Biology, 19, 815-827. https://doi.org/10.1016/S0945-053X(00)00133-5
Puolakkainen, P.A., Brekken, R.A., Muneer, S. and Sage, E.H. (2004) Enhanced Growth of Pancreatic Tumors in SPARC-Null Mice Is Associated with Decreased Deposition of Extracellular Matrix and Reduced Tumor Cell Apoptosis. Molecular Cancer Research, 2, 215-224.
Sato, N., Fukushima, N., Maehara, N., Matsubayashi, H., Koopmann, J., Su, G.H., Hruban, R.H. and Goggins, M. (2003) SPARC/Osteonectin Is a Frequent Target for Aberrant Methylation in Pancreatic Adenocarcinoma and a Mediator of Tumor-Stromal Interactions. Oncogene, 22, 5021-5030. https://doi.org/10.1038/sj.onc.1206807
Nagai, M.A., Gerhard, R. Fregnani, J.H., Nonogaki, S., Rierger, R.B., Netto, M.M. and Soares, F.A. (2011) Prognostic Value of NDRG1 and SPARC Protein Expression in Breast Cancer Patients. Breast Cancer Research and Treatment, 126, 1-14. https://doi.org/10.1007/s10549-010-0867-2
Guweidhi, A., Kleeff, J., Adwan, H., Giese, N.A., Wente, M.N., Giese, T., Buchler, M.W., Berger, M.R. and Friess, H. (2005) Osteonectin Influences Growth and Invasion of Pancreatic Cancer Cells. Annals of Surgery, 242, 224-234. https://doi.org/10.1097/01.sla.0000171866.45848.68
Brekken, R.A., Puolakkainen, P., Graves, D.C., Workman, G., Lubkin, S.R. and Sage, E.H. (2003) Enhanced Growth of Tumors in SPARC Null Mice Is Associated with Changes in the ECM. The Journal of Clinical Investigation, 111, 487-495. https://doi.org/10.1172/JCI16804